Perinatal Stroke: High-Dose Therapy Improves Arm Function

A significant advancement in pediatric stroke recovery has emerged from the American Stroke Association’s International Stroke Conference 2026: high-dose, home-based constraint-induced movement therapy (CIMT) demonstrably improves arm function in infants and toddlers who have experienced perinatal stroke. This finding is particularly impactful because perinatal arterial ischemic stroke (PAIS) – stroke occurring before or shortly after birth – is the most common type of stroke in children, and historically, prognoses have been cautiously pessimistic. The I-ACQUIRE trial results challenge that narrative, offering a new level of optimism for families and a potential paradigm shift in early intervention strategies.

PAIS often results in hemiparesis, a weakness on one side of the body, impacting a child’s ability to perform everyday tasks. CIMT, a therapy designed to force use of the affected limb while restricting the stronger arm, has shown promise in older children and adults. However, adapting this therapy for infants and toddlers presented unique challenges. The I-ACQUIRE protocol addressed these by incorporating a structured parent component and delivering therapy within the child’s natural environment – their home. The trial, conducted across 15 US centers and involving 167 children aged 8-36 months, rigorously compared high-dose (120 hours), moderate-dose (60 hours), and usual care (approximately 1 hour/week of occupational and physical therapy).

While both I-ACQUIRE dose groups showed improvements over usual care at the end of treatment, the high-dose group maintained a significant advantage at the 6-month follow-up. Interestingly, even the usual care group demonstrated clinically meaningful improvements, a finding that researchers attribute to increased awareness and attention to motor skills following enrollment in the study. However, parent-reported outcomes indicated that these gains in the usual care group didn’t translate to sustained functional improvements in daily life, underscoring the value of intensive, targeted therapy.

The Forward Look

The I-ACQUIRE trial represents a crucial first step, but several key questions remain. The variability in treatment response observed – some children benefiting far more than others – necessitates further investigation. Future research will likely focus on identifying biomarkers or clinical characteristics that predict which infants will respond most favorably to high-dose CIMT. This could involve genetic analysis, advanced neuroimaging techniques, or detailed assessments of the initial stroke severity and location. Furthermore, the study’s limitations regarding site selection and the exclusion of some initially enrolled participants highlight the need for larger, more diverse trials to confirm these findings and establish generalizability.

Beyond refining patient selection, the success of the I-ACQUIRE protocol points to the potential for expanding access to intensive, home-based therapies for pediatric stroke. This could involve telehealth platforms, remote monitoring of therapy adherence, and increased training for parents to deliver the intervention effectively. The positive impact on parental expectations, as reported by researchers, is also noteworthy. Empowering families with a sense of agency and hope is a critical component of long-term recovery. Finally, the study’s findings are likely to influence clinical guidelines and insurance coverage for early intervention services for infants with PAIS, potentially leading to earlier and more effective treatment for this vulnerable population. We can anticipate a surge in demand for specialized pediatric stroke rehabilitation programs and a greater emphasis on family-centered care in the coming years.

References

1. American Heart Association. High-dose therapy had lasting benefits for infants with stroke before or soon after birth. American Heart Association. February 6, 2026. Accessed February 6, 2026. https://newsroom.heart.org/news/high-dose-therapy-had-lasting-benefits-for-infants-with-stroke-before-or-soon-after-birth
2. i-Acquire. NIH. 2026. Accessed February 6, 2026. https://www.nihstrokenet.org/trials/i-acquire/home